Serina Therapeutics, INC 10-Q quarterly reports

Serina Therapeutics, Inc. reported a net loss of $6.36 million for the quarter ended June 30, 2026, and faces substantial doubt about its ability to continue as a going concern.

Serina Therapeutics reports increased operating expenses and net loss for Q1 2026, but significant cash infusion from financing activities bolsters liquidity.

Serina Therapeutics reported increased losses and a clinical hold on its lead Parkinson's drug, raising substantial doubt about its ability to continue as a going concern.

Serina Therapeutics, a clinical-stage biotech, reported a significant net loss in Q2 2025, alongside a going concern warning, despite active capital raising and pipeline advancement.

Serina Therapeutics reports a net loss of $4.8 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Serina Therapeutics reports its Q3 2024 results, highlighting a net loss of $8.4 million and ongoing concerns about its ability to continue as a going concern.

Serina Therapeutics reports its second quarter 2024 results, which include the impact of a recent merger and highlight ongoing financial challenges.

Serina Therapeutics reports a net loss of $9.4 million for the first quarter of 2024, following a merger and facing substantial doubt about its ability to continue as a going concern.